A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Clinical trial NCT06407934 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06407934
- Sponsor
- Sanofi
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-08
- Primary completion
- 2026-06-10
- Enrollment
- 1541
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.